Released : October 22, 2020 18:22 RNS Number : 9790C MaxCyte, Inc. 22 October 2020 Disclosure of Remuneration for Non-Audit Services Gaithersburg, Maryland - 22 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an
Released : October 14, 2020 07:00 RNS Number : 9794B MaxCyte, Inc. 14 October 2020 Notification of Annual General Meeting and Declaration of Audit Remuneration Gaithersburg, Maryland - 14 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences
Released : October 13, 2020 07:00 RNS Number : 8523B MaxCyte, Inc. 13 October 2020 MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments Gaithersburg, Maryland - 13 October 2020: MaxCyte, Inc.
Released : October 01, 2020 07:00 RNS Number : 6925A MaxCyte, Inc. 01 October 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Maryland, USA - 1 October 2020 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company, announces that J.
Released : September 21, 2020 07:00 RNS Number : 5084Z MaxCyte, Inc. 21 September 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2020 · Strong revenue growth of 30%, generating positive EBITDA (before CARMA investment) · Significant
Released : September 10, 2020 13:42 RNS Number : 6540Y MaxCyte, Inc. 10 September 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of options Gaithersburg, Maryland - 10 September 2020: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Released : September 10, 2020 07:00 RNS Number : 5403Y MaxCyte, Inc. 10 September 2020 MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference GAITHERSBURG, MD , 10 September 2020 - MaxCyte, Inc.
Released : September 09, 2020 07:00 RNS Number : 3947Y MaxCyte, Inc. 09 September 2020 MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer - Murphy brings a wealth of life sciences capital markets
Released : September 02, 2020 14:57 RNS Number : 8572X MaxCyte, Inc. 02 September 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : September 02, 2020 07:00 RNS Number : 7362X MaxCyte, Inc. 02 September 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Gaithersburg, Maryland - 2 September 2020 - MaxCyte, Inc.
